| Title: | Cystatin C is associated with adverse COVID-19 outcomes in diverse populations |
| Journal: | iScience |
| Published: | 31 Aug 2022 |
| Pubmed: | https://pubmed.ncbi.nlm.nih.gov/36062073/ |
| DOI: | https://doi.org/10.1016/j.isci.2022.105040 |
| URL: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9428108 |
| Citations: | 2 (2 in last 2 years) as of 8 Aug 2024 |
Publication 7403
WARNING: the interactive features of this website use CSS3, which your browser does not support. To use the full features of this website, please update your browser.
Abstract
COVID-19 has highly variable clinical courses. The search for prognostic host factors for COVID-19 outcome is a priority. We performed logistic regression for ICU admission against a polygenic score (PGS) for Cystatin C (CyC) production in patients with COVID-19. We analyzed the predictive value of longitudinal plasma CyC levels in an independent cohort of patients hospitalized with COVID-19. In four cohorts spanning European and African ancestry populations, we identified a significant association between CyC-production PGS and odds of critical illness (n cases=2,319), with the strongest association captured in the UKB cohort (OR 2.13, 95% CI 1.58-2.87, p=7.12e-7). Plasma proteomics from an independent cohort of hospitalized COVID-19 patients (n cases = 131) demonstrated that CyC production was associated with COVID-specific mortality (p=0.0007). Our findings suggest that CyC may be useful for stratification of patients and it has functional role in the host response to COVID-19.14 Authors
- Sam O. Kleeman
- Mattia Cordioli
- Paul R.H. J. Timmers
- Atlas Khan
- Pinkus Tober-Lau
- Florian Kurth
- Vadim Demichev
- Hannah V. Meyer
- James F. Wilson
- Markus Ralser
- Krzysztof Kiryluk
- Andrea Ganna
- Kenneth Baillie
- Tobias Janowitz
Enabling scientific discoveries that improve human health